Circulating microRNA expression signatures accurately discriminate myalgic encephalomyelitis from fibromyalgia and comorbid conditions.
Nepotchatykh, Evguenia, Caraus, Iurie, Elremaly, Wesam et al. · Scientific reports · 2023 · DOI
Quick Summary
Researchers studied tiny molecules called microRNAs in the blood to see if they could tell the difference between ME/CFS, fibromyalgia, and people who have both conditions. They found that each condition has a unique pattern of these microRNAs, like a biological fingerprint. Using these patterns, they created a computer model that could accurately identify which condition a person has, which could help with proper diagnosis.
Why It Matters
Accurate biomarkers could resolve the persistent diagnostic confusion between ME/CFS and fibromyalgia, leading to proper treatment and preventing inappropriate therapeutic approaches. This work provides evidence that ME/CFS is a distinct biological condition, supporting validation efforts and potentially improving recognition of the comorbid state. Such biomarkers could accelerate research into disease mechanisms and enable patient stratification for future clinical trials.
Observed Findings
Eleven circulating miRNAs showed differential expression patterns across ME/CFS, FM, and ME/CFS+FM groups compared to healthy controls.
miRNA expression signatures correlated with symptom severity in both ME/CFS and ME/CFS+FM patient groups.
A machine-learning model using the 11 miRNAs achieved accurate discrimination between ME/CFS, FM, and comorbid ME/CFS+FM.
The miRNA profiles suggested ME/CFS and FM have distinct underlying biological mechanisms despite symptom overlap.
Inferred Conclusions
ME/CFS and fibromyalgia are biologically distinct diseases with separate molecular signatures.
Circulating miRNAs represent potential diagnostic biomarkers for differentiating ME/CFS from FM and identifying comorbid disease.
Proper diagnosis using molecular markers could improve treatment strategies and disease understanding for both conditions.
Patients with comorbid ME/CFS+FM have a distinct miRNA profile differing from either condition alone.
Remaining Questions
Have these 11 miRNAs been validated in independent cohorts, and do they retain discriminatory power across diverse patient populations?
What are the specific biological pathways affected by these miRNAs, and how do they relate to ME/CFS pathophysiology?
What This Study Does Not Prove
This study does not establish that these miRNAs cause ME/CFS or fibromyalgia—it shows association only. The findings require independent validation in larger, prospective cohorts before clinical implementation. The study cannot clarify whether miRNA changes reflect primary disease pathology or secondary adaptations to chronic illness.